Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
Fabi A, Carbognin L, Botticelli A, Paris I, Fuso P, Savastano MC, La Verde N, Strina C, Pedersini R, Guarino S, Curigliano G, Criscitiello C, Raffaele M, Beano A, Franco A, Valerio MR, Verderame F, Fontana A, Haspinger ER, Caldara A, Di Leone A, Tortora G, Giannarelli D, Scambia G. Fabi A, et al. Among authors: pedersini r. NPJ Breast Cancer. 2023 Sep 8;9(1):73. doi: 10.1038/s41523-023-00579-2. NPJ Breast Cancer. 2023. PMID: 37684252 Free PMC article.
EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer.
Biganzoli L, Cinieri S, Berardi R, Pedersini R, McCartney A, Minisini AM, Caremoli ER, Spazzapan S, Magnolfi E, Brunello A, Risi E, Palumbo R, Leo S, Colleoni M, Donati S, De Placido S, Orlando L, Pistelli M, Parolin V, Mislang A, Becheri D, Puglisi F, Sanna G, Zafarana E, Boni L, Mottino G. Biganzoli L, et al. Among authors: pedersini r. Breast Cancer Res. 2020 Aug 5;22(1):83. doi: 10.1186/s13058-020-01319-1. Breast Cancer Res. 2020. PMID: 32758299 Free PMC article. Clinical Trial.
Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET).
Vernieri C, Nichetti F, Lalli L, Moscetti L, Giorgi CA, Griguolo G, Marra A, Randon G, Rea CG, Ligorio F, Scagnoli S, De Angelis C, Molinelli C, Fabbri A, Ferraro E, Trapani D, Milani A, Agostinetto E, Bernocchi O, Catania G, Vantaggiato A, Palleschi M, Moretti A, Basile D, Cinausero M, Ajazi A, Castagnoli L, Lo Vullo S, Gerratana L, Puglisi F, La Verde N, Arpino G, Rocca A, Ciccarese M, Pedersini R, Fabi A, Generali D, Losurdo A, Montemurro F, Curigliano G, Del Mastro L, Michelotti A, Cortesi E, Guarneri V, Pruneri G, Mariani L, de Braud F. Vernieri C, et al. Among authors: pedersini r. Clin Cancer Res. 2021 Jun 15;27(12):3443-3455. doi: 10.1158/1078-0432.CCR-20-4928. Epub 2021 Mar 30. Clin Cancer Res. 2021. PMID: 33785482 Free article.
Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection.
Parati MC, Pedersini R, Perego G, Reduzzi R, Savio T, Cabiddu M, Borgonovo K, Ghilardi M, Luciani A, Petrelli F. Parati MC, et al. Among authors: pedersini r. Breast Cancer (Dove Med Press). 2022 Apr 12;14:101-111. doi: 10.2147/BCTT.S341857. eCollection 2022. Breast Cancer (Dove Med Press). 2022. PMID: 35440873 Free PMC article. Review.
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors.
Zattarin E, Presti D, Mariani L, Sposetti C, Leporati R, Menichetti A, Corti C, Benvenuti C, Fucà G, Lobefaro R, Ligorio F, Provenzano L, Vingiani A, Del Vecchio M, Griguolo G, Sirico M, Bernocchi O, Marra A, Zagami P, Agostinetto E, Jacobs F, Di Mauro P, Esposito A, Giorgi CA, Lalli L, Boldrini L, Giacchetti PPB, Schianca AC, Guarneri V, Pedersini R, Losurdo A, Zambelli A, Generali D, Criscitiello C, Curigliano G, Pruneri G, de Braud F, Dieci MV, Vernieri C. Zattarin E, et al. Among authors: pedersini r. NPJ Breast Cancer. 2023 Apr 17;9(1):27. doi: 10.1038/s41523-023-00534-1. NPJ Breast Cancer. 2023. PMID: 37069173 Free PMC article.
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study.
Di Lisa FS, Krasniqi E, Pizzuti L, Barba M, Cannita K, De Giorgi U, Borella F, Foglietta J, Cariello A, Ferro A, Picardo E, Mitidieri M, Sini V, Stani S, Tonini G, Santini D, La Verde N, Gambaro AR, Grassadonia A, Tinari N, Garrone O, Sarobba G, Livi L, Meattini I, D'Auria G, Vergati M, Gamucci T, Pistelli M, Berardi R, Risi E, Giotta F, Lorusso V, Rinaldi L, Artale S, Cazzaniga ME, Zustovich F, Cappuzzo F, Landi L, Torrisi R, Scagnoli S, Botticelli A, Michelotti A, Fratini B, Saltarelli R, Paris I, Muratore M, Cassano A, Gianni L, Gaspari V, Veltri EM, Zoratto F, Fiorio E, Fabbri MA, Mazzotta M, Ruggeri EM, Pedersini R, Valerio MR, Filomeno L, Minelli M, Scavina P, Raffaele M, Astone A, De Vita R, Pozzi M, Riccardi F, Greco F, Moscetti L, Giordano M, Maugeri-Saccà M, Zennaro A, Botti C, Pelle F, Cappelli S, Cavicchi F, Vizza E, Sanguineti G, Tomao F, Cortesi E, Marchetti P, Tomao S, Speranza I, Sperduti I, Ciliberto G, Vici P. Di Lisa FS, et al. Among authors: pedersini r. Front Oncol. 2023 May 16;13:1152123. doi: 10.3389/fonc.2023.1152123. eCollection 2023. Front Oncol. 2023. PMID: 37260975 Free PMC article.
Is weight gain preventable in women with early breast cancer undergoing chemotherapy? A real-world study on dietary pattern, physical activity, and body weight before and after chemotherapy.
Pedersini R, Laganà M, Bosio S, Zanini B, Cosentini D, di Mauro P, Alberti A, Schivardi G, Laini L, Ippolito G, Amoroso V, Vassalli L, Simoncini EL, Berruti A, Donato F. Pedersini R, et al. Breast Cancer Res Treat. 2023 Dec;202(3):461-471. doi: 10.1007/s10549-023-07095-8. Epub 2023 Sep 11. Breast Cancer Res Treat. 2023. PMID: 37695400 Free PMC article.
79 results